z-logo
Premium
Mechanism and function of decreased FOXO1 in renal cell carcinoma
Author(s) -
Zhou Libin,
Yin Bingde,
Liu Yongchao,
Hong Yan,
Zhang Changcun,
Fan Jie
Publication year - 2011
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.23013
Subject(s) - foxo1 , immunohistochemistry , cancer research , western blot , renal cell carcinoma , medicine , cell growth , downregulation and upregulation , cell , transfection , immunostaining , pathology , biology , cell culture , signal transduction , gene , protein kinase b , microbiology and biotechnology , genetics , biochemistry
Background and Objectives Forkhead box O‐class 1 (FOXO1), a putative tumor suppressor, is dysregulated in many cancers. Our study aims to reveal the underlying functions and regulation mechanisms of FOXO1 in renal cell carcinoma (RCC). Methods The clinical significance of FOXO1 expression in surgically resected specimens was assessed by immunohistochemistry. The siRNAs targeted FOXO1 and miR‐27a inhibitor were transfected into RCC cells. QRT‐PCR, Western blot, and cell proliferation assay were used to assess the expression and function of FOXO1 and miR‐27a. Results The positive immunostaining for FOXO1 was low in 51 RCC samples compared with 15 normal kidney tissues. And the expression of FOXO1 was related with RCC subtypes and the grade and stage in clear cell RCC (cRCC) ( P  < 0.05). Inhibition of FOXO1 promoted proliferation of 769‐P cells. However, upregulation of FOXO1 by miR‐27a inhibitor was accompanied by the anti‐proliferative effect in cells of 786‐O and Caki‐1. Furthermore, the expression of FOXO1 mRNA and miR‐27a had inverse relation in eight cRCC samples. Conclusion Reduced expression of FOXO1 is common in RCC and a potentially suitable marker of different histological subtypes and prognosis of cRCC. Increasing expression of FOXO1 by the miR‐27a inhibitor could prevent cell growth. J. Surg. Oncol. 2012; 105:841–847. © 2011 Wiley Periodicals, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here